Key Highlights

  • Gossamer Bio shares surged about 41.25% Monday to $0.19, up from a prior close of $0.14.
  • The company received official FDA meeting minutes from a Pre-NDA Type B meeting, outlining a path to a September 2026 NDA submission for seralutinib in pulmonary arterial hypertension.
  • Gossamer reacquired worldwide development and commercial rights to seralutinib from Chiesi, ending a prior 50/50 U.S. profit-sharing arrangement.
  • The stock carries a market capitalization of approximately $45.06 million, with a 52-week range of $0.11 to $3.87.

FDA Update and Rights Reacquisition Drive Sharp Rally

Gossamer Bio, Inc. (NASDAQ:GOSS) shares jumped sharply Monday after the company announced a series of regulatory, strategic and corporate updates that investors viewed as materially de-risking its path toward commercialization. The centerpiece of the announcement was confirmation that, following a Pre-NDA Type B meeting with the FDA, the company is proceeding toward a planned New Drug Application submission for seralutinib in pulmonary arterial hypertension in September 2026.

Gossamer Bio is a clinical-stage biopharmaceutical company headquartered in San Diego, California, focused on the development and commercialization of seralutinib, an inhaled small molecule inhibitor targeting PDGFR, CSF1R and c-KIT, for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. According to the company, the FDA characterized the degree of statistical significance and the magnitude of the treatment effect observed in the Phase 3 PROSERA study as review issues rather than filing issues, supporting the company's plan to submit an NDA backed by the PROSERA study alongside supportive data from the Phase 2 TORREY study.

Separately, Gossamer and Chiesi agreed to terminate their prior collaboration and license agreement, with Gossamer reacquiring full worldwide development and commercial rights to seralutinib. The termination dissolves the previous U.S. 50/50 profit-sharing structure and returns ex-U.S. rights to Gossamer, giving the company full operational control over development, manufacturing, commercialization, pricing and lifecycle strategy across all geographies. Chiesi will make a one-time $5 million payment to Gossamer and is entitled to a capped royalty on worldwide net sales going forward.

Balance Sheet Actions and Capital Structure

Gossamer's stockholders also approved proposals at a special meeting on July 14 related to a previously completed exchange of its 5.00% Convertible Senior Notes due 2027, along with authorization for the board to effect a reverse stock split. Through the exchange, the company converted approximately $181.1 million, or 90.5%, of its $200.0 million in outstanding 2027 notes into new secured notes, reducing aggregate debt principal by approximately $115.9 million.

Gossamer Bio shares traded within an intraday range of $0.15 to $0.21, with trading volume reaching 224.98 million shares, sharply above typical levels. The company reported preliminary cash, cash equivalents and marketable securities of approximately $57 million as of June 30, 2026. The reverse stock split is expected to take effect in or shortly following the third quarter of 2026, intended to support compliance with Nasdaq's minimum bid price requirement.

Conclusion

Gossamer Bio's sharp rally reflects investor enthusiasm following a cluster of catalysts that together clarify the company's regulatory path, restore full commercial control over its lead asset, and strengthen its balance sheet. Investors are likely to watch for the planned September NDA submission and further details on the timing of the reverse stock split.

This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.